Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

UK Reimbursement Decisions Focus Mostly On Cancer

Jun 15 2017

• By Sukaina Virji

Digital illustration of Cancer cell in colour background

Related Content

Intercept Boosts NASH Commercial Potential Via NICE Rare Disease Move

Mar 02 2017

Lilly's Sarcoma Drug Likely To Be Used Widely Despite EU Conditional OK

Nov 14 2016

NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut

Nov 17 2016

Myeloma Survival Benefit May Help Amgen's <em>Kyprolis</em> Stave Off Competition

Mar 01 2017

Related Companies

Roche Holding AG

Bristol Myers Squibb Company

Ipsen SA

Merck & Co., Inc.

Intercept Pharmaceuticals, Inc.

Eli Lilly and Company

Amgen, Inc.

Additional Topics

United Kingdom Europe Health Technology Assessment Market Access Policy Reimbursement BioPharmaceutical

More from United Kingdom

More from Europe

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window